[{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase III","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"10","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"PharmaEssentia","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Undisclosed","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Ointment","sponsorNew":"PharmaEssentia \/ PharmaEssentia","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ PharmaEssentia"},{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Hanmi Pharmaceutical \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Hanmi Pharmaceutical \/ Undisclosed"},{"orgOrder":0,"company":"PharmaEssentia","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Src kinase||Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase I","graph3":"PharmaEssentia","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaEssentia \/ Athenex","highestDevelopmentStatusID":"6","companyTruncated":"PharmaEssentia \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2016","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Kinex Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Oncology","graph2":"Phase I","graph3":"Kinex Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Kinex Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Kinex Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"TKL Research, Inc.","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ TKL Research, Inc.","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ TKL Research, Inc."},{"orgOrder":0,"company":"Athenex","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Oncology","graph2":"Phase II","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Athenex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Athenex \/ Undisclosed"},{"orgOrder":0,"company":"Medical University of Graz","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"AUSTRIA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Phase IV","graph3":"Medical University of Graz","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Medical University of Graz \/ Almirall","highestDevelopmentStatusID":"11","companyTruncated":"Medical University of Graz \/ Almirall"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Athenex","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Athenex","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Athenex"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Almirall","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Almirall","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Almirall \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Almirall \/ Undisclosed"},{"orgOrder":0,"company":"Skin Center Dermatology Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Skin Center Dermatology Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Skin Center Dermatology Group \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Skin Center Dermatology Group \/ Undisclosed"},{"orgOrder":0,"company":"Athenex","sponsor":"Almirall","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Almirall","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Almirall"},{"orgOrder":0,"company":"Athenex","sponsor":"PharmaEssentia","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ PharmaEssentia","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ PharmaEssentia"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"},{"orgOrder":0,"company":"Athenex","sponsor":"Seqirus","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2021","type":"Licensing Agreement","leadProduct":"Tirbanibulin","moa":"Tyrosine-protein kinase SRC","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Athenex","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Ointment","sponsorNew":"Athenex \/ Seqirus","highestDevelopmentStatusID":"15","companyTruncated":"Athenex \/ Seqirus"}]
Find Clinical Drug Pipeline Developments & Deals for Tirbanibulin
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
